skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアおすすめコンテンツ製品ログインProductLogin
Global Search Configuration
  • Close Icon

About Amanda

Connecticut, USA

+19 year(s) experience

As Principal Analyst for Datamonitor Healthcare, Amanda Micklus provides coverage of corporate strategy and deal-making trends. She writes strategy reports for Datamonitor Healthcare, alongside articles and other content for In Vivo and Strategic Transactions.

With a focus on research and analysis of corporate strategy and deal-making, Amanda provides analysis of market-moving events that influence business development at leading companies.

 

Her particular areas of expertise include big pharma licensing and immuno-oncology deal-making, R&D strategies and pharma diversification.

Before joining Informa in 2005, Amanda worked as a market research analyst at specialty pharmaceutical company Purdue Pharma and had a previous role as a medical librarian/information searcher.

She has a Bachelor of Science degree in Chemistry-Business from the University of Scranton, and a Master of Science in Library and Information Science from Long Island University.

Specialties

  • Oncology
  • Business Development & Licensing
  • Commercial Strategy

Amanda Writes For

Analyst Articles

Articles by Brian

  • Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

    Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

    By Brian Yang 02 Jul 2019

    Bagging a $200m box office in its opening week in China, "Dying to Survive" is a sentimental movie about a Chinese businessman selling cancer drugs smuggled from India but unapproved in China that sees his life taking a drastic turn, from convicted felon to a Robin Hood-like hero as he helps those in need. The Chinese film authority’s clearance for the screening of the movie and the smash success signal three key messages about the future potential direction of oncology drugs in the country.

    Topic cancer

    article

  • Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

    How To Deliver Your China Growth Story: Trends To Watch

    23 May 2019

    Caught between a grueling centralized bidding process and now potentially in trade war crossfire, foreign pharma firms have a lot on their plates in China. To succeed in this highly uncertain environment, observers point to the need to pursue excellence in multiple areas: product launches, medical coverage, the broad market and digital health.

    article

  • Scrip：世界の医薬品産業ニュースサービス

    Art Of War: Why Pharma Must Do Digital Dance In China

    06 Sep 2018

    “Winning the war without fighting. Using five types of fire attacks.” Sounds familiar? Sun Tzu's 2,000 year-old wisdom on the art of war is echoing down the ages, and winning in China today means that pharma needs to embrace a digital strategy more than ever before.

    Topic digital-health

    article

  • Scrip：世界の医薬品産業ニュースサービス

    Chindia Generics: A Dream or Reality?

    30 Aug 2018

    Meeting and greeting is necessary, as is the right form of partnership and getting everyone on board. But as Indian drug makers learn the ropes of entering the complex Chinese market, the seemingly natural fit may still have a long way to go.

    Topic business-strategies

    article

  • Scrip：世界の医薬品産業ニュースサービス

    Hong Kong Takes On Nasdaq For China Biotech IPOs

    09 Aug 2018

    Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.

    Topic Policy and regulation

    View article

  • Pink Sheet：世界の薬事規制と承認審査に関するニュース

    Goodbye CFDA, Hello MRA: China Overhauls Regulatory Bodies

    20 Mar 2018

    China proposes to merge its top drug regulator into new combined body, and creates a medical reimbursement agency in move viewed as sign of strengthening regulatory oversight.

    Topic reimbursement drug-review

    article

  • Scrip：世界の医薬品産業ニュースサービス

    Mooncakes Under The Sun: Can China's ‘Name And Shame’ Rule Create Level Playing Field?

    04 Oct 2017

    China's proposal to register all medical sales reps could lead to the eventual elimination of kickbacks to physicians.

    article

  • Pink Sheet：世界の薬事規制と承認審査に関するニュース

    Focused China Local Strategy Remains Key Despite Country's Joining ICH – Executives

    29 Sep 2017

    Top China executives from Pfizer, AstraZeneca, GSK share their views on growing in China amid lingering challenges despite regulatory progress.

    View article

  • Scrip：世界の医薬品産業ニュースサービス

    How To Make A Global First-In-Class Drug In China

    08 Mar 2017

    The story so far of how an aspiring Western returnee researcher became a fully charged pharma entrepreneur in China’s wild world of drug innovation.

    article